Published in Blood Weekly, February 16th, 2006
"Obesity is becoming increasingly common worldwide and is strongly associated with the metabolic syndrome (MetS). MetS is considered to be a cluster of risk factors that increase the risk of vascular events," scientists writing in the journal Current Medical Research and Opinion report.
T.D. Filippatos and colleagues at the University of Ioannina explained, "In an open-label randomized study (the FenOrli study) we assessed the effect of orlistat and fenofibrate treatment, alone or in combination on reversing the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.